Search results
Results from the WOW.Com Content Network
Siltuximab (INN [4]), sold under the brand name Sylvant, is used for the treatment of people with multicentric Castleman's disease. [2] [3] It is a chimeric (made from human and mouse proteins) monoclonal antibody that binds to interleukin-6. It is an interleukin-6 (IL-6) antagonist. [2]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
In the United States treatment with biologic drugs typically costs US$2,000 –6,000 per month, [4] compared to US$12 –600 per month for conventional (small-molecule) DMARDs. [ 27 ] References
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient. [ 30 ] Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
Immune stimulating antibody conjugates work by activating dendritic cells within the tumor, [3] and are capable of being delivered systemically. [4] With some patients being resistant to checkpoint inhibitors , immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like ...